



## References and Resources

Araujo EG, Englbrecht M, Hoepken et al. Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PsA patients with active enthesitis—results from the enthesial clearance in psoriatic arthritis study [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10).

<http://acrabstracts.org/abstract/ustekinumab-is-superior-to-tnf-inhibitor-treatment-in-resolving-enthesitis-in-psa-patients-with-active-enthesitis-results-from-the-enthesial-clearance-in-psoriatic-arthritis-study/>. Accessed January 18, 2018.

Coates LC, Gladman DD, Nash P, et al. Secukinumab achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) related remission: 2-Year results from a phase 3 Study [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/secukinumab-achievement-of-psoriatic-arthritis-disease-activity-score-pasdas-related-remission-2-year-results-from-a-phase-3-study/>. Accessed January 18, 2018.

Coates L, Gladman D, Nash P, et al. SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study. *Ann Rheum Dis.* 2017;76:948-949.

Kirkham B, Helliwell P, Korendowych E, et al. Assessing Psoriatic Arthritis in your clinic: Training manual for Trainer. UK PsA Assessment Academy. October 2015. Available at <https://www.psoriatic-arthritis.co.uk/Assets/Files/Content/PsA%20Training%20Manual.pdf>

McInnes IB, et al. 2016 ACR/ARHP Annual meeting abstract supplement. *Arthritis Rheumatol.* 2016;68 (suppl 10:1–4550). doi: 10.1002/art.39977.

Mease PJ, Burmester GR, Moriarty S, Benichou O, Xu W, Nash P. Ixekizumab exhibits a favorable safety profile during 24 weeks of treatment in subjects with active psoriatic arthritis: Integrated safety analysis of two randomized, placebo controlled, phase III clinical trials [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/ixekizumab-exhibits-a-favorable-safety-profile-during-24-weeks-of-treatment-in-subjects-with-active-psoriatic-arthritis-integrated-safety-analysis-of-two-randomized-placebo-controlled-phase-iii-cl/>. Accessed January 18, 2018.

Mease PJ, Kellner H, Morita A, et al. Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/efficacy-and-safety-results-from-a-phase-2-trial-of-risankizumab-a-selective-il-23p19-inhibitor-in-patients-with-active-psoriatic-arthritis/>. Accessed January 18, 2018.

Mease PJ, McInnes IB, Reich K, et al. Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate to severe plaque psoriasis: Updated pooled safety analyses [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/secukinumab-demonstrates-consistent-safety-over-long-term-exposure-in-patients-with-psoriatic-arthritis-and-moderate-to-severe-plaque-psoriasis-updated-pooled-safety-analyses/>. Accessed January 29, 2018.

Mease PJ, van der Heijde D, Landewé RBM, et al. Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/subcutaneous-secukinumab-inhibits->

# PSORIATIC ARTHRITIS

## Posters and Abstracts from San Diego

 ANNENBERG CENTER FOR HEALTH SCIENCES  
AT EISENHOWER  
Imparting knowledge. Improving patient care.



radiographic-progression-in-psoriatic-arthritis-primary-results-from-a-large-randomized-controlled-double-blind-phase-3-study/. Accessed January 18, 2018.

Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the second interim analysis of OPAL balance, an open-label, long-term extension study [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <http://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-an-oral-janus-kinase-inhibitor-up-to-36-months-in-patients-with-active-psoriatic-arthritis-data-from-the-second-interim-analysis-of-opal-balance-an-open-label-extension-study/>. Accessed January 29, 2018.

Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. *J Am Acad Dermatol.* 2017;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026.